Vimarsana
Biggest News Aggregation in the World

Catalyst Pharms News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Catalyst Pharms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Catalyst Pharms Today - Breaking & Trending Today

Senate Once Again Tries to Address Drug Pricing | McDonnell Boehnen Hulbert & Berghoff LLP - Vimarsana News

Senate Once Again Tries to Address Drug Pricing | McDonnell Boehnen Hulbert & Berghoff LLP

Over the past several years Congress has tried to address high drug prices, with variable success  (see "FTC to the Rescue Regarding High Drug Prices and Patents"; "Even More...

Resistance Or Defiance The FDA And The 11th Circuit Spar Over Statute On Orphan Drug Statutory Exclusivity - Vimarsana News

Resistance Or Defiance The FDA And The 11th Circuit Spar Over Statute On Orphan Drug Statutory Exclusivity

Last September, the 11th Circuit Court of Appeals sided with a challenge to the FDA’s long-standing interpretation of the Orphan Drug Act by...

Health Care Week in Review: Record-Breaking Marketplace Enrollments and Reproductive Healthcare Actions | Alston & Bird - Vimarsana News

Health Care Week in Review: Record-Breaking Marketplace Enrollments and Reproductive Healthcare Actions | Alston & Bird

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and...

FDA Doubles Down on Its Pre-Catalyst Stance on Orphan Drug Exclusivity | Cooley LLP - Vimarsana News

FDA Doubles Down on Its Pre-Catalyst Stance on Orphan Drug Exclusivity | Cooley LLP

On January 24, 2023, the Food and Drug Administration published a notice in the Federal Register to “address the uncertainty” created by the US Court of Appeals for the Eleventh...

Pharma Investment Trend Report: What We're Watching in 2023 | King & Spalding - Vimarsana News

Pharma Investment Trend Report: What We're Watching in 2023 | King & Spalding

2022 was a big year for the pharmaceutical and biotechnology sectors. Novel technologies emerged at a rapid clip. The Food and Drug Administration (“FDA” or the “Agency”) approved over...